Contents8 sections
The Ipamorelin + CJC-1295 stack is the most widely used growth hormone secretagogue combination in the peptide space. The pairing works because each compound stimulates GH release through a different receptor pathway — Ipamorelin acts on the ghrelin receptor (GHS-R1a) while CJC-1295 acts on GHRH receptors. This dual-pathway approach produces greater GH output than either peptide alone while maintaining the body’s natural pulsatile secretion pattern.
Both compounds have documented GH-releasing properties in human studies. Ipamorelin has been shown to selectively stimulate growth hormone without significantly affecting cortisol, prolactin, or other pituitary hormones. CJC-1295 demonstrated sustained GH elevation with dose-dependent increases in IGF-1 levels over multi-week administration periods. Combined, these mechanisms create the foundation for the Ipamorelin CJC-1295 stack’s popularity.
Key Takeaways
- The stack combines two GH secretagogues that work through different receptor pathways (ghrelin vs. GHRH) for synergistic growth hormone release.
- Ipamorelin provides acute GH pulses while CJC-1295 extends the duration of GH elevation.
- Common protocol: 200-300 mcg Ipamorelin + 100 mcg CJC-1295 (no DAC), administered 1-3 times daily via subcutaneous injection.
- The CJC-1295 “no DAC” version (also called Mod GRF 1-29) is preferred for stacking due to shorter, more controllable GH pulses.
- Side effects are generally mild. Neither compound suppresses natural hormone production, so PCT is not required.
How the Ipamorelin + CJC-1295 Stack Works
Ipamorelin: The GH Pulse Trigger
Ipamorelin is a pentapeptide growth hormone secretagogue that binds to GHS-R1a (ghrelin) receptors on the pituitary gland. When activated, these receptors trigger a burst of GH release into the bloodstream. What distinguishes Ipamorelin from older secretagogues like GHRP-6 is its selectivity — it stimulates GH release without the side effects of increased cortisol, aldosterone, or prolactin that other ghrelin-receptor agonists produce.
The compound has a half-life of approximately 2 hours, making it suitable for multiple daily administrations that mimic the body’s natural GH pulsatility.
CJC-1295 (No DAC): The Duration Extender
CJC-1295 without DAC — also known as Mod GRF 1-29 — is a modified growth hormone-releasing hormone analog consisting of 29 amino acids. It binds to GHRH receptors on the pituitary, amplifying and extending the GH release triggered by Ipamorelin. Its half-life is approximately 30 minutes, which is long enough to sustain the GH pulse without producing the prolonged, non-physiological GH elevation that the DAC (Drug Affinity Complex) version creates.
DAC vs. No DAC
| Feature | CJC-1295 No DAC (Mod GRF 1-29) | CJC-1295 with DAC |
|---|---|---|
| Half-life | ~30 minutes | ~6-8 days |
| GH release pattern | Pulsatile (natural) | Sustained (less natural) |
| Dosing frequency | 1-3x daily | 1-2x per week |
| Stacking compatibility | Preferred for Ipamorelin stacking | Less ideal — sustained release conflicts with pulsatile approach |
| Pituitary feedback | Preserves natural regulation | May blunt pituitary sensitivity |
The no DAC version is the standard choice for the Ipamorelin CJC-1295 stack because it matches Ipamorelin’s pulsatile release pattern. The DAC version keeps GH elevated continuously, which can desensitize the pituitary over time and produces a less physiological GH profile.
The Synergy
When injected together, Ipamorelin activates the ghrelin pathway while CJC-1295 activates the GHRH pathway simultaneously. These two signaling cascades converge on the same somatotroph cells in the pituitary, and research on GHRH analogs suggests that concurrent activation of both pathways produces a greater GH response than either pathway alone. The result is a robust but time-limited GH pulse that rises quickly, peaks within 15-30 minutes, and returns to baseline within 2-3 hours.
Ipamorelin CJC-1295 Benefits
Fat Loss and Body Composition
The primary Ipamorelin CJC-1295 benefit for body composition is enhanced lipolysis driven by elevated GH levels. Growth hormone activates hormone-sensitive lipase in adipose tissue, mobilizing stored fat for energy use. The pulsatile GH release from this stack preferentially targets visceral fat — the metabolically active fat surrounding internal organs that contributes to cardiovascular risk and insulin resistance.
Users typically report noticeable CJC-1295 Ipamorelin results in body composition after 8-12 weeks, with improvements in waist circumference and abdominal definition. The fat loss effect is enhanced when combined with structured training and a caloric deficit.
Muscle Recovery and Growth
Elevated GH and IGF-1 levels support protein synthesis, nitrogen retention, and tissue repair. While the Ipamorelin CJC-1295 stack is not anabolic in the same category as steroids, it supports recovery between training sessions and may contribute to lean mass gains over time. Athletes and bodybuilders often report faster recovery from intense sessions and reduced muscle soreness.
For users specifically targeting muscle growth with peptides, the stack provides a GH-mediated foundation that complements training and nutrition rather than replacing them.
Sleep Quality
Growth hormone is naturally released in its largest pulse during deep sleep. By administering the stack before bedtime, users amplify this natural GH surge. Improved sleep depth and quality is one of the most consistently reported CJC-1295 Ipamorelin results, often noticeable within the first 1-2 weeks of use. Better sleep cascades into improved recovery, cognitive function, and energy levels.
Skin, Hair, and Anti-Aging
Elevated IGF-1 stimulates collagen synthesis and cellular renewal. Users frequently report improvements in skin elasticity, reduced fine lines, and improved hair texture over 8-16 weeks of consistent use. These effects are consistent with the known role of GH/IGF-1 in tissue maintenance and repair.
Ipamorelin CJC-1295 Dosage
Standard Protocols
| Protocol | Ipamorelin | CJC-1295 (No DAC) | Frequency | Timing |
|---|---|---|---|---|
| Beginner | 100-200 mcg | 100 mcg | 1x daily | Before bed |
| Standard | 200-300 mcg | 100 mcg | 2x daily | Morning + before bed |
| Advanced | 300 mcg | 100-200 mcg | 3x daily | Morning + post-workout + before bed |
Administration Guidelines
- Injection method: Subcutaneous injection into the abdomen or thigh. Both peptides can be drawn into the same syringe and injected together.
- Timing: Administer on an empty stomach (at least 2 hours after eating, 30 minutes before eating). The bedtime dose is the most important — it aligns with the natural nocturnal GH pulse.
- Reconstitution: Each vial is reconstituted with bacteriostatic water. Store refrigerated and use within 21 days of mixing.
- Injection sites: Rotate injection sites to prevent tissue irritation and lipodystrophy at frequently used locations.
- Cycle length: 8-16 weeks on, followed by 4 weeks off. The off period allows pituitary sensitivity to reset and prevents receptor desensitization.
Ipamorelin CJC-1295 Dosage Notes
The most common mistake is overdosing. Higher doses do not produce proportionally greater GH release — the pituitary has a saturation point beyond which additional peptide provides diminishing returns while increasing side effects like water retention and numbness. Starting at the lower end and titrating upward based on response and bloodwork (IGF-1 levels) is the most effective approach.
Ipamorelin CJC-1295 Side Effects
The Ipamorelin CJC-1295 side effects profile is mild compared to most performance compounds, partly because both peptides work through the body’s natural GH signaling rather than introducing exogenous hormones.
Reported Side Effects
| Side Effect | Frequency | Notes |
|---|---|---|
| Injection site redness/irritation | Common | Standard for subcutaneous peptides; rotate sites |
| Water retention | Occasional | Mild puffiness in hands/feet; dose-dependent |
| Headache | Occasional | More common in the first 1-2 weeks |
| Tingling/numbness | Uncommon | Sign of elevated GH; reduce dose if persistent |
| Nausea | Rare | Usually related to injecting on a full stomach |
| Increased hunger | Rare (Ipamorelin only) | Less pronounced than with GHRP-6 or GHRP-2 |
Safety Considerations
- No HPTA suppression: Neither Ipamorelin nor CJC-1295 affects testosterone production, estrogen, or the hypothalamic-pituitary-gonadal axis. Post-cycle therapy is not required.
- Blood glucose: As with all GH-elevating compounds, extended use may affect insulin sensitivity. Monitor fasting glucose during longer cycles, especially if pre-diabetic.
- Cancer contraindication: Elevated GH/IGF-1 may theoretically stimulate growth in existing malignancies. Individuals with active cancer should not use GH secretagogues.
- Cortisol: Unlike GHRP-2 and GHRP-6, Ipamorelin does not significantly raise cortisol or prolactin levels. This is one of its primary advantages as a stacking component.
Ipamorelin + CJC-1295 vs Other GH Protocols
| Feature | Ipamorelin + CJC-1295 | Tesamorelin | Sermorelin | Exogenous HGH |
|---|---|---|---|---|
| Mechanism | Dual pathway (ghrelin + GHRH) | GHRH agonist only | GHRH analog (first generation) | Direct GH replacement |
| GH release | Pulsatile, synergistic | Pulsatile, single pathway | Pulsatile, lower potency | Constant, supraphysiological |
| Half-life | ~2 hr (Ipa) + ~30 min (CJC) | ~26 min | ~10-20 min | ~3-4 hours |
| Pituitary suppression | No | No | No | Yes |
| FDA status | Research chemical | FDA-approved (Egrifta) | Previously FDA-approved (discontinued) | FDA-approved |
| PCT required | No | No | No | May be needed |
| Cost | Moderate | High | Moderate | Very high |
| Best for | General GH optimization | Visceral fat reduction | Entry-level GH support | Maximum GH elevation |
The Ipamorelin CJC-1295 stack offers the broadest benefit profile among secretagogue protocols because it activates two separate GH pathways simultaneously. Tesamorelin has stronger clinical evidence for visceral fat reduction specifically. Exogenous HGH produces the highest absolute GH levels but suppresses pituitary function and costs significantly more.
The Bottom Line
The Ipamorelin + CJC-1295 stack earns its reputation as the standard GH secretagogue protocol for good reason.
- The dual-pathway mechanism produces synergistic GH release while preserving natural pulsatility, the side effect profile is mild, and neither compound requires PCT.
- For users seeking improved body composition, recovery, sleep quality, and general anti-aging support through GH optimization, this stack offers the most balanced combination of effectiveness and tolerability in the secretagogue class.
- Proper Ipamorelin CJC-1295 dosage (start low, titrate up), empty-stomach timing, consistent daily administration, and cycling with off-periods to maintain pituitary sensitivity is key to reaping the benefits of this stack.
Hello – I’ve read some literature debating pros and cons of CJC 1295 DAC vs no DAC.
If ipamorelin/CJC is administered once per day – say 300mg each, is there any real risk of using DAC version for 90 day experiment?
I understand that CJC 1295 is more natural and supports shorter bursts, while DAC instead leads to a more sustained release.
Is that sustained release a serious legitimate risk of impacting/shutting off the pituitary?